Replimune Sets Virtual Annual Meeting for Sept. 3, Urges Proxy Votes
Ticker: REPL · Form: DEF 14A · Filed: Jul 25, 2025 · CIK: 1737953
| Field | Detail |
|---|---|
| Company | Replimune Group, Inc. (REPL) |
| Form Type | DEF 14A |
| Filed Date | Jul 25, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: Proxy Statement, Annual Meeting, Corporate Governance, Biotechnology, Shareholder Vote, Virtual Meeting, SEC Filing
Related Tickers: REPL
TL;DR
**REPL's virtual annual meeting on Sept 3rd is a must-vote for shareholders to shape the company's future, don't just sit on your hands!**
AI Summary
Replimune Group, Inc. (REPL) filed a DEF 14A proxy statement on July 25, 2025, for its Annual Meeting of Stockholders scheduled for September 3, 2025, at 11:30 a.m. Eastern Time. The meeting will be entirely virtual, accessible via www.meetnow.global/MF6VJVT. The proxy materials, including the Annual Report for the fiscal year ended March 31, 2025, were first sent to stockholders around July 25, 2025. Stockholders of record as of July 16, 2025, are eligible to vote on the matters described in the Proxy Statement. The filing emphasizes the importance of stockholder participation and voting, even if not attending the virtual meeting. Specific financial figures for revenue and net income are not detailed in this DEF 14A, as it primarily outlines the procedural aspects of the upcoming annual meeting and voting process. Key business changes, risks, and strategic outlook are typically covered in the accompanying Annual Report, which is referenced but not summarized here.
Why It Matters
This DEF 14A filing is crucial for Replimune investors as it outlines the procedural framework for the 2025 Annual Meeting, where key corporate governance decisions will be made. Investor participation in voting on board elections, executive compensation, and other proposals directly impacts the company's strategic direction and accountability. For employees and customers, the outcomes of these votes can influence long-term stability and operational focus. In the competitive biotech landscape, strong governance and clear investor mandates are vital for Replimune to maintain investor confidence and pursue its biological product development, especially against rivals in the oncology space.
Risk Assessment
Risk Level: low — The risk level is low because this DEF 14A filing is a standard procedural document for an annual meeting, primarily detailing logistics like the September 3, 2025 meeting date and the July 16, 2025 record date. It does not contain new financial disclosures or significant operational changes that would introduce immediate market risk. The filing simply informs stockholders about their voting rights and the virtual meeting format.
Analyst Insight
Investors should carefully review the full Proxy Statement and the Annual Report for the fiscal year ended March 31, 2025, which were sent around July 25, 2025. It is imperative to cast your vote on all proposals by the September 3, 2025 meeting date, even if not attending the virtual meeting, to ensure your voice is heard on corporate governance matters.
Key Players & Entities
- Replimune Group, Inc. (company) — Registrant and issuer of the DEF 14A
- September 3, 2025 (date) — Date of the 2025 Annual Meeting of Stockholders
- July 16, 2025 (date) — Record date for stockholders entitled to vote at the Annual Meeting
- July 25, 2025 (date) — Date the Notice of Internet Availability of Proxy Materials was first sent
- Woburn, MA (location) — Business address of Replimune Group, Inc.
- 500 Unicorn Park Drive Suite 303 (location) — Street address of Replimune Group, Inc.
- 11:30 a.m., Eastern Time (time) — Scheduled start time of the Annual Meeting
- www.meetnow.global/MF6VJVT (website) — Virtual meeting platform for the Annual Meeting
- March 31, 2025 (date) — End of the fiscal year for the Annual Report referenced
- SEC (regulator) — United States Securities and Exchange Commission
FAQ
When is Replimune Group, Inc.'s 2025 Annual Meeting of Stockholders?
Replimune Group, Inc.'s 2025 Annual Meeting of Stockholders is scheduled for Wednesday, September 3, 2025, at 11:30 a.m., Eastern Time. This information is clearly stated in the DEF 14A filing.
How can stockholders attend Replimune's 2025 Annual Meeting?
Stockholders can attend Replimune's 2025 Annual Meeting virtually via live webcast by visiting www.meetnow.global/MF6VJVT. The meeting will be a completely virtual event, as specified in the DEF 14A.
What is the record date for voting at Replimune's 2025 Annual Meeting?
The record date for voting at Replimune's 2025 Annual Meeting is July 16, 2025. All holders of record of common stock at the close of business on this date are entitled to vote.
What documents were sent to Replimune stockholders on or about July 25, 2025?
On or about July 25, 2025, Replimune sent stockholders a Notice of Internet Availability of Proxy Materials, which contains instructions on how to access the Proxy Statement and the Annual Report for the fiscal year ended March 31, 2025.
What is the purpose of Replimune's DEF 14A filing?
The purpose of Replimune's DEF 14A filing is to serve as a definitive proxy statement, providing stockholders with important information about the upcoming 2025 Annual Meeting and the matters to be voted upon, ensuring compliance with Section 14(a) of the Securities Exchange Act of 1934.
Where is Replimune Group, Inc. headquartered?
Replimune Group, Inc. is headquartered at 500 Unicorn Park Drive, Suite 303, Woburn, MA 01801. This business address is listed in the DEF 14A filing.
Why is it important for Replimune stockholders to vote even if they don't attend the virtual meeting?
It is important for Replimune stockholders to vote even if they don't attend the virtual meeting because their shares need to be represented and voted on the matters scheduled. The company explicitly states this to ensure all stockholders have an opportunity to participate in corporate governance.
What type of company is Replimune Group, Inc. based on its SIC code?
Based on its Standard Industrial Classification (SIC) code 2836, Replimune Group, Inc. is classified under 'Biological Products (No Diagnostic Substances)'. This indicates its focus on developing biological products.
What is the fiscal year end for Replimune Group, Inc.?
The fiscal year end for Replimune Group, Inc. is March 31. This is relevant as the DEF 14A references the Annual Report for the fiscal year ended March 31, 2025.
Will Replimune's Annual Meeting have in-person attendance?
No, Replimune's 2025 Annual Meeting will not have in-person attendance. The DEF 14A explicitly states that it will be a 'completely virtual meeting of stockholders' and attendees 'will not be able to attend the Annual Meeting in person.'
Industry Context
Replimune Group operates in the biotechnology sector, specifically focusing on the development of oncolytic immunotherapies. This is a highly competitive and rapidly evolving field driven by scientific innovation and significant R&D investment. Key trends include advancements in gene editing, personalized medicine, and the increasing focus on combination therapies to enhance treatment efficacy.
Regulatory Implications
As a biotechnology company, Replimune is subject to stringent regulatory oversight from bodies like the FDA. Approval processes for new therapies are lengthy and complex, with potential delays or rejections posing significant risks. Compliance with evolving clinical trial regulations and manufacturing standards is critical for continued operation and product development.
What Investors Should Do
- Review the Proxy Statement and Annual Report.
- Vote your shares.
- Attend the virtual Annual Meeting.
Key Dates
- 2025-07-25: Proxy materials (DEF 14A and Annual Report) first sent to stockholders. — Informs shareholders about the upcoming annual meeting and provides information for voting.
- 2025-07-16: Record date for determining stockholders entitled to vote. — Establishes the list of shareholders who have the right to vote at the Annual Meeting.
- 2025-09-03: 2025 Annual Meeting of Stockholders. — The date for the virtual meeting where key company matters will be voted upon by shareholders.
Glossary
- DEF 14A
- A Definitive Proxy Statement filed with the SEC, providing detailed information about matters to be voted on at a company's annual meeting. (This is the primary document filed by Replimune, outlining the agenda and voting procedures for their annual shareholder meeting.)
- Proxy Statement
- A document that the SEC requires companies to provide to shareholders before their annual meeting, containing information about the meeting agenda, board nominees, executive compensation, and other relevant business. (This document guides shareholders on how to vote and what to expect at the Replimune annual meeting.)
- Annual Report
- A comprehensive report on a company's activities throughout the preceding year, including financial statements and management's discussion and analysis. (Provides detailed financial and operational performance information for the fiscal year ended March 31, 2025, referenced in the proxy statement.)
- Record Date
- A specific date set by a company to determine which shareholders are eligible to receive notice of and vote at a shareholder meeting. (July 16, 2025, is the record date for Replimune, meaning only shareholders who owned stock on this date can vote.)
Year-Over-Year Comparison
This DEF 14A filing for the 2025 Annual Meeting focuses on procedural aspects and voting matters, referencing the Annual Report for detailed financial performance. Specific comparative financial metrics like revenue growth or margin changes from the prior fiscal year are not detailed within this proxy statement itself. Investors should refer to the accompanying Annual Report for a comprehensive year-over-year financial comparison and analysis of business risks and strategic developments.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on July 25, 2025 regarding Replimune Group, Inc. (REPL).